This site is intended for healthcare professionals

Novartis reports positive topline results from the first phase III trial of Beovu versus aflibercept in patients with diabetic macular edema (DME).

Read time: 1 mins
Last updated:14th Sep 2020
Published:15th Sep 2020
Condition: Diabetic Macular Oedema
Type: drug
Register free for full access to